- Home
- MBCN vs SGMT Comparison
MBCN vs SGMT Comparison
Compare MBCN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBCN
- SGMT
- Stock Information
- Founded
- MBCN 1901
- SGMT 2006
- Country
- MBCN United States
- SGMT United States
- Employees
- MBCN N/A
- SGMT N/A
- Industry
- MBCN Major Banks
- SGMT
- Sector
- MBCN Finance
- SGMT
- Exchange
- MBCN Nasdaq
- SGMT Nasdaq
- Market Cap
- MBCN 236.1M
- SGMT 269.2M
- IPO Year
- MBCN N/A
- SGMT 2023
- Fundamental
- Price
- MBCN $31.14
- SGMT $9.64
- Analyst Decision
- MBCN Hold
- SGMT Strong Buy
- Analyst Count
- MBCN 1
- SGMT 5
- Target Price
- MBCN $32.00
- SGMT $26.60
- AVG Volume (30 Days)
- MBCN 11.2K
- SGMT 2.0M
- Earning Date
- MBCN 07-21-2025
- SGMT 08-13-2025
- Dividend Yield
- MBCN 2.69%
- SGMT N/A
- EPS Growth
- MBCN N/A
- SGMT N/A
- EPS
- MBCN 2.00
- SGMT N/A
- Revenue
- MBCN $66,931,000.00
- SGMT N/A
- Revenue This Year
- MBCN $15.08
- SGMT N/A
- Revenue Next Year
- MBCN $5.02
- SGMT N/A
- P/E Ratio
- MBCN $15.12
- SGMT N/A
- Revenue Growth
- MBCN N/A
- SGMT N/A
- 52 Week Low
- MBCN $22.02
- SGMT $1.73
- 52 Week High
- MBCN $34.00
- SGMT $10.43
- Technical
- Relative Strength Index (RSI)
- MBCN 58.79
- SGMT 68.58
- Support Level
- MBCN $30.44
- SGMT $7.80
- Resistance Level
- MBCN $32.10
- SGMT $9.89
- Average True Range (ATR)
- MBCN 0.90
- SGMT 0.95
- MACD
- MBCN 0.07
- SGMT -0.01
- Stochastic Oscillator
- MBCN 75.52
- SGMT 76.43
About MBCN Middlefield Banc Corp.
Middlefield Banc Corp is a bank holding company. It offers customers, banking services including checking, savings, negotiable order of withdrawal (NOW) accounts, money market accounts, time deposits, commercial loans, real estate loans, a variety of consumer loans, safe deposit facilities, and travelers' checks. It also provides online banking and bill payment services to individuals and online cash management services to business customers.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.